Drugs / IBI314
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05162365 | Jan → Jun 2022 | COVID-19 | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05172141 | Dec 2021 → Aug 2022 | COVID-19 | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05172141 ↗ |
| Modality | Monoclonal antibody | “a cocktail of two SARS-CoV-2 S protein IgG1 antibodies” NCT05162365 ↗ |
| Route | Intravenous | “administered as a single IV infusion” NCT05162365 ↗ |